Identifying patients at high risk for <font color="red">neutropenic_1</font> <font color="red">complications_1</font> during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin : the <font color="red">development_1</font> <font color="red">of_1</font> <font color="red">a_1</font> <font color="red">prediction_1</font> <font color="red">model_1</font> <font color="red">._1</font> 
<br>
<br> OBJECTIVE <font color="red">To_1</font> <font color="red">develop_1</font> <font color="red">a_1</font> <font color="red">cycle_1</font> <font color="red">-_1</font> <font color="red">based_1</font> <font color="red">risk_1</font> <font color="red">prediction_1</font> <font color="red">model_1</font> <font color="red">for_1</font> <font color="red">neutropenic_2</font> <font color="red">complications_2</font> <font color="red">(_2</font> <font color="red">NC_2</font> <font color="red">)_2</font> <font color="red">during_1</font> <font color="red">chemotherapy_1</font> <font color="red">with_1</font> <font color="red">doxorubicin_1</font> <font color="red">(_1</font> <font color="red">DOX_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">a_1</font> <font color="red">pegylated_1</font> <font color="red">liposomal_1</font> <font color="red">formulation_1</font> <font color="red">(_1</font> <font color="red">PLD_1</font> <font color="red">)_1</font> <font color="red">for_1</font> <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">metastatic_1</font> <font color="red">breast_1</font> <font color="red">cancer_1</font> <font color="red">(_1</font> <font color="red">MBC_1</font> <font color="red">)_1</font> <font color="red">._1</font> <font color="red">
<br>_1</font> METHODS Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg / m(2 ) every 3 weeks ) or PLD ( 50 mg / m(2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol . 2004;15:440 - 449 ) . <font color="red">NC_1</font> <font color="red">were_1</font> <font color="red">defined_1</font> <font color="red">as_1</font> <font color="red">an_1</font> <font color="red">absolute_2</font> <font color="red">neutrophil_2</font> <font color="red">count_2</font> <font color="red"><_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">1.5_1</font> <font color="red">x_1</font> <font color="red">10(9_1</font> <font color="red">)_1</font> <font color="red">cells_1</font> <font color="red">/_1</font> <font color="red">L_1</font> <font color="red">(_1</font> <font color="red">ie_1</font> <font color="red">,_1</font> <font color="red">>_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">grade_1</font> <font color="red">II_1</font> <font color="red">)_1</font> <font color="red">before_1</font> <font color="red">the_1</font> <font color="red">next_1</font> <font color="red">cycle_1</font> <font color="red">,_1</font> <font color="red">febrile_1</font> <font color="red">neutropenia_1</font> <font color="red">or_1</font> <font color="red">neutropenia_1</font> <font color="red">with_1</font> <font color="red">a_1</font> <font color="red">documented_1</font> <font color="red">infection_1</font> <font color="red">._1</font> <font color="red">Patient_1</font> <font color="red">and_1</font> <font color="red">hematologic_1</font> <font color="red">factors_1</font> potentially associated with NC were evaluated . Factors with a P value of < or = 0.25 within a cycle were included in a generalized estimating equations regression model . Using backward elimination , we derived <font color="red">a_1</font> <font color="red">risk_1</font> <font color="red">scoring_1</font> <font color="red">algorithm_1</font> ( range 0 - 63 ) from the final reduced model . 
<br> RESULTS Risk factors retained in the model included <font color="red">poor_1</font> <font color="red">performance_1</font> <font color="red">status_1</font> <font color="red">,_1</font> <font color="red">absolute_1</font> <font color="red">neutrophil_1</font> <font color="red">count_1</font> <font color="red"><_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">2.0_1</font> <font color="red">x_1</font> <font color="red">10(9_1</font> <font color="red">)_1</font> <font color="red">cells_1</font> <font color="red">/_1</font> <font color="red">L_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">previous_1</font> <font color="red">cycle_1</font> <font color="red">,_1</font> <font color="red">the_1</font> <font color="red">first_1</font> <font color="red">cycle_1</font> <font color="red">of_1</font> <font color="red">chemotherapy_1</font> <font color="red">,_1</font> <font color="red">DOX_1</font> <font color="red">versus_1</font> <font color="red">PLD_1</font> <font color="red">and_1</font> <font color="red">advanced_1</font> <font color="red">age_1</font> <font color="red">._1</font> <font color="red">A_1</font> <font color="red">precycle_1</font> <font color="red">risk_1</font> <font color="red">score_1</font> <font color="red">from_1</font> <font color="red">>_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">25_1</font> <font color="red">to_1</font> <font color="red"><_1</font> <font color="red">40_1</font> <font color="red">for_1</font> <font color="red">a_1</font> <font color="red">given_1</font> <font color="red">patient_1</font> <font color="red">was_1</font> <font color="red">identified_1</font> <font color="red">as_1</font> <font color="red">being_1</font> <font color="red">the_1</font> <font color="red">optimal_1</font> <font color="red">threshold_1</font> <font color="red">for_1</font> <font color="red">sensitivity_1</font> <font color="red">(_1</font> <font color="red">58.0%_1</font> <font color="red">)_1</font> <font color="red">and_1</font> <font color="red">specificity_1</font> <font color="red">(_1</font> <font color="red">78.7%_1</font> <font color="red">)_1</font> <font color="red">._1</font> <font color="red">Patients_1</font> <font color="red">with_1</font> <font color="red">a_1</font> <font color="red">score_1</font> <font color="red">at_1</font> <font color="red">or_1</font> <font color="red">beyond_1</font> <font color="red">this_1</font> <font color="red">threshold_1</font> <font color="red">would_1</font> <font color="red">be_1</font> <font color="red">considered_1</font> <font color="red">at_1</font> <font color="red">high_1</font> <font color="red">risk_1</font> <font color="red">for_1</font> <font color="red">developing_1</font> <font color="red">NC_1</font> <font color="red">in_1</font> <font color="red">later_1</font> <font color="red">cycles_1</font> <font color="red">._1</font> 
<br> CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those MBC patients most likely to experience NC during anthracycline - based chemotherapy .